 |
Photo = Celtrion |
[Alpha Biz= Kim Jisun] Celltrion announced on July 3 that it will appeal a court ruling in a civil lawsuit with Humasis over a COVID-19 test kit partnership, after the Seoul Central District Court ruled partially in favor of Humasis in the first trial.
The court acknowledged Humasis’ delay in delivery and ordered the company to pay Celltrion KRW 3.89 billion (approx. USD 2.8 million) in damages. However, it rejected Celltrion's claim that it was justified in terminating the contract, and ruled that Celltrion must pay Humasis KRW 12.71 billion (approx. USD 9.1 million) for undelivered goods and related compensation.
As a result, Celltrion faces a net payment of approximately KRW 8.82 billion (approx. USD 6.3 million).
In a statement, Celltrion said:
“While we respect the court’s decision, we express regret over certain aspects of the ruling. We plan to appeal and will present clear evidence that the contract termination was both inevitable and justified.”
The legal dispute began with Humasis suing Celltrion for unpaid amounts and damages related to undelivered COVID-19 test kits. In response, Celltrion filed a counterclaim citing repeated delays and sought the return of advance payments.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
